MAPT and red-green color blindness: To assess the antibodies’ ability to detect Tau in clinically relevant human brain samples, the immunoreactivity pattern of “total” Tau antibodies was tested in human brain protein extracts from control individuals and donors diagnosed with one of four different tauopathies: AD, PSP, CBD, and PiD.